<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="99718"><DrugName>H3B-6527</DrugName><DrugSynonyms><Name><Value>FGFR-4 inhibitors (cancer), Eisai/H3 Biomedicine</Value></Name><Name><Value>H3B-6527</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1059601">H3 Biomedicine Inc</CompanyOriginator><CompaniesPrimary><Company id="1059601">H3 Biomedicine Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1059601" type="Company"><TargetEntity id="5035455484" type="organizationId">H3 Biomedicine Inc</TargetEntity></SourceEntity><SourceEntity id="1765" type="ciIndication"><TargetEntity id="D018281" type="MeSH"></TargetEntity><TargetEntity id="70567" type="ORPHANET"></TargetEntity><TargetEntity id="-2122101383" type="omicsDisease"></TargetEntity><TargetEntity id="1844" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"></TargetEntity><TargetEntity id="88673" type="ORPHANET"></TargetEntity><TargetEntity id="-1116061312" type="omicsDisease"></TargetEntity><TargetEntity id="1973" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3691" type="Action"><TargetEntity id="3838" type="Mechanism">FGFR4 Inhibitors</TargetEntity><TargetEntity id="6163" type="Mechanism">Anti-FGFR4</TargetEntity></SourceEntity><SourceEntity id="PTGT-00739" type="ciTarget"><TargetEntity id="166694595022643" type="siTarget">Fibroblast growth factor receptor 4</TargetEntity><TargetEntity id="263" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C1">Phase 1 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1765">Cholangiocarcinoma</Indication><Indication id="1767">Hepatocellular carcinoma</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="3691">FGF4 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="586">Capsule formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-01-05T17:06:20.000Z</LastModificationDate><ChangeDateLast>2019-01-08T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-04T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15872" linkType="Company"&gt;Eisai&lt;/ulink&gt;, through its subsidiary  &lt;ulink linkID="1059601" linkType="Company"&gt;H3 Biomedicine&lt;/ulink&gt;,  is developing H3B-6527, a lead from a program of FGFR4 inhibitors, for the potential oral treatment of cancer, including advanced hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHCC)      [&lt;ulink linkID="1708599" linkType="Reference"&gt;1708599&lt;/ulink&gt;], [&lt;ulink linkID="1709061" linkType="Reference"&gt;1709061&lt;/ulink&gt;], [&lt;ulink linkID="1164186" linkType="Reference"&gt;1164186&lt;/ulink&gt;]. In July 2016, a phase I trial in HCC and IHCC began  [&lt;ulink linkID="1781231" linkType="Reference"&gt;1781231&lt;/ulink&gt;]. At that time, the drug was listed as being in phase I development in the US and Japan [&lt;ulink linkID="1781080" linkType="Reference"&gt;1781080&lt;/ulink&gt;]. In January 2018, phase Ib  combination studies were expected  that year  [&lt;ulink linkID="1996079" linkType="Reference"&gt;1996079&lt;/ulink&gt;]. In January 2019,  phase I development was ongoing [&lt;ulink linkID="2108319" linkType="Reference"&gt;2108319&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In September 2017, the FDA granted the drug Orphan designation for treatment of HCC [&lt;ulink linkID="1962988" linkType="Reference"&gt;1962988&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In July 2017, the COMP of the EMA recommended granting the drug Orphan status for treatment of HCC [&lt;ulink linkID="1948897" linkType="Reference"&gt;1948897&lt;/ulink&gt;]; in August 2017, the Orphan designation was granted [&lt;ulink linkID="1965438" linkType="Reference"&gt;1965438&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In January 2018, the company planned to start phase Ib combination studies with H3B-6527 and to determine the phase II dose during that year  [&lt;ulink linkID="1996079" linkType="Reference"&gt;1996079&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2017, a randomized, single-group assigned, open-label phase I trial (&lt;ulink linkID="328605" linkType="Protocol"&gt;NCT03424577&lt;/ulink&gt;; H3B-6527-A001-001) was initiated in the US, to evaluate the effect of food on the relative bioavailability of H3B-6527 in healthy male individuals (expected n = 17). Subjects would receive either H3B-6527  with food on day 1 and  without food on day 5 (fed/fasted), or H3B-6527 without food on day 1 and H3B-6527 with food on day 5 (fasted/fed). In January 2018, the trial was completed [&lt;ulink linkID="2043862" linkType="Reference"&gt;2043862&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2016, an open-label multicenter phase I study (&lt;ulink linkID="265770" linkType="Protocol"&gt;NCT02834780&lt;/ulink&gt;; H3B-6527-G000-101; 2016-001915-19) was initiated to evaluate the safety, pharmacokinetics and pharmacodynamics of H3B-6527 in subjects (expected n = 90, Taiwan n = 5) with advanced HCC and IHCC [&lt;ulink linkID="1781231" linkType="Reference"&gt;1781231&lt;/ulink&gt;]. In April 2017, recruitment was ongoing in the US, Canada and Spain. At that time, trial completion was expected in January 2019 [&lt;ulink linkID="1781231" linkType="Reference"&gt;1781231&lt;/ulink&gt;]. By July 2017,  recruitment  had  started in Taiwan [&lt;ulink linkID="1944713" linkType="Reference"&gt;1944713&lt;/ulink&gt;]. In September 2017, the trial was extended to Singapore and to South Korea in January 2018 [&lt;ulink linkID="1781231" linkType="Reference"&gt;1781231&lt;/ulink&gt;]. In June 2018, recruitment was ongoing with 105 patients expected to enroll. At that time, trial completion was expected in June 2020 [&lt;ulink linkID="1781231" linkType="Reference"&gt;1781231&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015,  phase I trials were planned to begin later in 2015 [&lt;ulink linkID="1709061" linkType="Reference"&gt;1709061&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In September 2018, in vivo data were presented at 12th International Liver Cancer Association Annual Conference in London, UK. In mice bearing HEP3B cell line xenografts, combination of H3B-6527 and lenvatinib demonstrated tumor regressions at dose levels where single agents did not. In mice  H3B-6527 and lenvatinib  demonstrated tumor growth inhibition at  well tolerated doses [&lt;ulink linkID="2079461" linkType="Reference"&gt;2079461&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2017, preclinical data were presented at the 11th International Liver Cancer Association Annual Conference in Seoul, Korea. The study demonstrated that  FGF19 expression was a predictive biomarker for response to H3B-6527 in non-clinical studies. The drug was &amp;gt;250 fold selective towards FGFR4 compared to other FGFR isoforms and led to a dose dependent inhibition of FGF19/FGFR4 signaling. Further, in a panel of 40 HCC cell lines, the drug selectively reduced the viability of cells that harbored FGF19 amplification and showed no effect in FGF19 non-amplified HCC cell line models. The drug demonstrated inhibition of tumor growth in an orthotopic liver xenograft model of FGF19 altered HCC grown in nude mice with no toxicities were observed at efficacious doses [&lt;ulink linkID="1962631" linkType="Reference"&gt;1962631&lt;/ulink&gt;]. Further in vivo data were presented at the same conference. In mice with HEP3B tumor xenograft, H3B-6527 led to dose-dependent robust modulation of CYP7A1 mRNA levels following one po dose and inhibition of sc and orthotopic tumor growth upon repeat dosing. In JHH7 xenograft models, H3B-6527 (500 mg/kg, po, bid) alone lead to tumor stasis, while H3B-6527 (500 mg/kg, po, bid) + palbociclib (100 mg/kg, po, qd) enhanced anti-tumor effect [&lt;ulink linkID="1998800" linkType="Reference"&gt;1998800&lt;/ulink&gt;]. In December 2017, similar data were also published [&lt;ulink linkID="1992037" linkType="Reference"&gt;1992037&lt;/ulink&gt;], [&lt;ulink linkID="1992115" linkType="Reference"&gt;1992115&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2017, preclinical data were presented at the 108th AACR Annual Meeting in Washington DC. H3B-6527 showed IC50 values of 318, 1290, 1060, &amp;lt; 1.25, 694, &amp;gt; 100,000 and 55,400 nM/l, against FGFR1, FGFR1, FGFR1, FGFR1, TAOK2, JNK2, CSF1R, respectively [&lt;ulink linkID="1913662" linkType="Reference"&gt;1913662&lt;/ulink&gt;] [&lt;ulink linkID="1907282" linkType="Reference"&gt;1907282&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, preclinical data were presented at the 9th ILCA Annual Conference in Paris, France. Addition of H3B-6527 to FGF19 amplified HCC cell lines led to dose dependent inhibition of FGF19/FGFR4 signaling and reduction in viability of cells. Pharmacodynamic modulation and tumor regression in FGF19 altered FGF19 altered HCC cell line derived xenograft and HCC patient derived xenograft without ant FGFR1 to 3 related toxicities were observed with H3B-6527 dosing in mice [&lt;ulink linkID="1725850" linkType="Reference"&gt;1725850&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, preclinical data were presented at the 9th ILCA  Conference  in Paris, France. In the study, H3B6527 was shown to be 300-fold more selective for FGFR-4, compared to other FGFR  isoforms. Dosing in mice led to tumor regression in FGF19-altered HCC cell line-derived and patient-derived xenografts, with no FGFR1-3 related toxicities observed [&lt;ulink linkID="1709020" linkType="Reference"&gt;1709020&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1059601">H3 Biomedicine Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-30T00:00:00.000Z</StatusDate><Source id="1781231" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1059601">H3 Biomedicine Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-26T00:00:00.000Z</StatusDate><Source id="1781231" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1059601">H3 Biomedicine Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-19T00:00:00.000Z</StatusDate><Source id="1781080" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1059601">H3 Biomedicine Inc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-09-07T00:00:00.000Z</StatusDate><Source id="1781231" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1059601">H3 Biomedicine Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-19T00:00:00.000Z</StatusDate><Source id="1781080" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1059601">H3 Biomedicine Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-19T00:00:00.000Z</StatusDate><Source id="1781080" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1059601">H3 Biomedicine Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-30T00:00:00.000Z</StatusDate><Source id="1781231" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1059601">H3 Biomedicine Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-30T00:00:00.000Z</StatusDate><Source id="1781231" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1059601">H3 Biomedicine Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-01-26T00:00:00.000Z</StatusDate><Source id="1781231" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1059601">H3 Biomedicine Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-30T00:00:00.000Z</StatusDate><Source id="1781231" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1059601">H3 Biomedicine Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-06T00:00:00.000Z</StatusDate><Source id="1944713" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1059601">H3 Biomedicine Inc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-09-07T00:00:00.000Z</StatusDate><Source id="1781231" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1059601">H3 Biomedicine Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-30T00:00:00.000Z</StatusDate><Source id="1944713" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1059601">H3 Biomedicine Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-19T00:00:00.000Z</StatusDate><Source id="1781080" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1059601">H3 Biomedicine Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-06T00:00:00.000Z</StatusDate><Source id="1709061" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1059601">H3 Biomedicine Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-06T00:00:00.000Z</StatusDate><Source id="1709061" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15872">Eisai Co Ltd</OwnerCompany><Country id="US">US</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of hepatocellular carcinoma (HCC)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-09-07T00:00:00.000Z</MileStoneDate><Source id="1962988" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15872">Eisai Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of hepatocellular carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-08-23T00:00:00.000Z</MileStoneDate><Source id="1965438" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15872">Eisai Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of hepatocellular carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-13T00:00:00.000Z</MileStoneDate><Source id="1948897" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00739"><Name>FGF4 receptor</Name><SwissprotNumbers><Swissprot>P22455</Swissprot><Swissprot>Q03142</Swissprot><Swissprot>Q498D6</Swissprot><Swissprot>Q90330</Swissprot><Swissprot>Q90413</Swissprot><Swissprot>Q91288</Swissprot><Swissprot>Q91743</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2108319" linkType="reference" linkID="2108319"&gt;2108319&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CCN1CCN(CC1)c2ccc(c(c2)NC(=O)C=C)Nc3cc(ncn3)N(C)C(=O)Nc4c(c(cc(c4Cl)OC)OC)Cl</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="2923201" number="WO-2015057938" title="Pyrimidine FGFR-4 inhibitors"></PatentFamily><PatentFamily id="3848237" number="WO-2017196854" title="Drug combinations for reducing cell viability and/or cell proliferation"></PatentFamily><PatentFamily id="3963974" number="WO-2018039324" title="Combination therapies for the treatment of hepatocellular carcinoma"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eisai Co Ltd" id="15872"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>